Why the study?
ACE inhibitors combined with mineralocorticoid receptor antagonists benefit chronic kidney disease, prompting evaluation of the antialbuminuric effects of ramipril, eplerenone, and their combination in stage 1 hypertension and type 2 diabetes.
Does combination therapy of eplerenone and ramipril reduce urinary albumin/creatinine ratio in hypertensive patients with type 2 diabetes mellitus and microalbuminuria compared to monotherapy?
Does combination therapy of eplerenone and ramipril reduce urinary albumin/creatinine ratio in hypertensive patients with type 2 diabetes mellitus and microalbuminuria compared to monotherapy?
The addition of eplerenone to ramipril provides an added antialbuminuric effect without significantly increasing serum potassium levels in patients with type 2 diabetic nephropathy.
Answers are grounded in this paper and cite their sources.
Supports adding eplerenone to ramipril for greater UACR reduction in T2DM nephropathy; extends dual RAAS blockade evidence beyond monotherapy.
Introduction: Angiotensin-converting enzyme inhibitors (ACEI) combined with mineralocorticoid receptor antagonists were found to have a beneficial effect on patients with chronic kidney disease. Objective: The aim of our clinical trial was to compare the antialbuminuric effect of ramipril monotherapy, eplerenone monotherapy and eplerenone/ramipril combination therapy in patients with stage 1 hypertension and type 2 diabetes mellitus. Methods: In a single-blind, randomized clinical trial, 75 hypertensive patients (stage 1 hypertension) with type 2 diabetes mellitus and microalbuminuria were randomized in a 1:1:1 ratio to 1 of 3 groups: ramipril 10 mg monotherapy (25 patients), eplerenone 50 mg monotherapy (25 patients) and combination therapy of eplerenone/ramipril 50/10 mg (25 patients) through a randomized clinical trial. Blood pressure, urinary albumin/creatinine ratio (UACR), serum creatinine, estimated glomerular filtration rate (eGFR) and serum K level were measured before randomization and after 24 weeks. Results: Ramipril and eplerenone monotherapy showed a significant lowering of UACR compared with baseline levels (p ≤ 0.0001). The eplerenone/ramipril combination group showed a more significant reduction of UACR compared with the ramipril and eplerenone monotherapy groups (p = 0.0001). There was a more significant lowering of systolic blood pressure in the combination group (p < 0.0001). A nonsignificant change of serum potassium level, serum creatinine and eGFR was found among the 3 groups. Conclusion: Addition of eplerenone to ACEI shows an added antialbuminuric effect without significant change of the serum K level compared with eplerenone or ACEI.
No takes yet. Share an insight, caveat, or question.
Mokadem et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: